The ELANE Knockout MCF-7 Polyclonal Cells represent a genetically disrupted population of the MCF-7 human breast adenocarcinoma cell line, engineered via CRISPR/Cas9-mediated disruption of the ELANE gene. This product is supplied as a polyclonal pool, consisting of a heterogeneous population of edited cells without clonal isolation, and is designed for researchers requiring a loss-of-function model for neutrophil elastase in an epithelial breast cancer background. The knockout strategy employs targeted gene disruption to abrogate ELANE expression, providing a versatile tool for applications in protease biology, inflammation research, and breast cancer microenvironment studies.
The parental MCF-7 cell line is a well-characterized epithelial model derived from the pleural effusion of a 69-year-old female with metastatic breast adenocarcinoma. These cells maintain an estrogen receptor-positive phenotype and are widely employed as a standard system for dissecting hormone-responsive signaling, tumor progression, and therapeutic responses in breast cancer. Their adherent growth, robust propagation, and extensive literature precedent make them a reliable host for genetic manipulation, particularly for investigating extraneous protease functions that are not endogenously expressed in this lineage.
ELANE encodes neutrophil elastase, a chymotrypsin-like serine protease primarily involved in the degradation of extracellular matrix components such as elastin, collagen, and fibronectin, as well as in the processing of pro-inflammatory cytokines. The enzyme is activated downstream of granulocyte colony-stimulating factor (G-CSF) and transcription factors C/EBP?? and SPI1 (PU.1), and its activity is physiologically counterbalanced by inhibitors including SERPINA1 (??1-antitrypsin), secretory leukocyte protease inhibitor (SLPI), and elafin. Upon release, neutrophil elastase cleaves and potentiates signaling molecules such as CXCL8, TNF-??, and IL-1??, and engages pathways involving TLR4, NF-??B, and MAPK1, ultimately promoting neutrophil extracellular trap (NET) formation through PADI4. In the MCF-7 context, which lacks endogenous elastase expression, the ELANE knockout provides a clean background for dissecting these proteolytic cascades when elastase is exogenously introduced or when studying cross-talk with stromal-derived proteases in co-culture models.
Given that MCF-7 cells do not naturally produce neutrophil elastase, this knockout model is particularly valuable as a negative control or for reconstitution experiments aimed at defining the protease??s contribution to breast cancer pathophysiology. The absence of ELANE facilitates unambiguous attribution of protease-dependent effects in assays where recombinant elastase or neutrophil-conditioned medium is applied, enabling precise mapping of substrate cleavage, cytokine activation, and downstream signaling events. Researchers can also exploit this system to validate the specificity of anti-ELANE antibodies, to screen small-molecule inhibitors without interference from endogenous enzyme, and to investigate the crosstalk between tumor cells and inflammatory mediators that may involve elastase released from infiltrating immune cells.
Common experimental applications include western blotting and RT-qPCR for confirming knockout efficiency, elastase activity assays to measure residual proteolysis, cytokine ELISAs for quantifying CXCL8 and TNF-?? secretion, and migration or invasion assays to assess functional consequences in breast cancer progression. In co-culture or xenograft models, these cells enable the study of tumor-immune interactions where neutrophil-derived elastase influences tumor growth and metastasis. Additional uses involve flow cytometric analysis of surface markers modulated by elastase cleavage, immunofluorescence for detecting NETosis components, and high-throughput screening for elastase inhibitors. For further details or custom inquiries, please contact Ascent Research.
